Celsion Corp expected to post a loss of $1.12 a share - Earnings Preview
Brief: Celsion Appoints Corinne Le Goff As President, CEO
Brief: Celsion Corp Says Novel Gene-Mediated Immunotherapy Is Safe And Demonstrates An Acceptable Risk/Benefit
Brief: Celsion Corp - On May 25, 2022, Co Entered Into At The Market Offering Agreement Pursuant To Which Co May Offer And Sell Shares Up To $7.5 Million
Celsion Corp reports results for the quarter ended in March - Earnings Summary
Brief: Celsion Corporation Reports First Quarter 2022 Financial Results
Celsion Corp expected to post a loss of 99 cents a share - Earnings Preview
Celsion Corp expected to post a loss of 99 cents a share - Earnings Preview
Brief: Celsion Corporation Highlights Pipeline Progress In Its Lead Development Candidates
Brief: Celsion Corporation Highlights Placcine Vaccine Platform Technology At The World Vaccine Congress
Celsion Corp reports results for the quarter ended in December - Earnings Summary
Brief: Celsion Corp Says Has Sufficient Capital Resources To Fund Its Operations Through End Of 2024
Celsion Corp expected to post a loss of 90 cents a share - Earnings Preview
Brief: Celsion Corp - On March 15, Received Written Notice From Nasdaq Notifying Co Has Regained Compliance With Minimum Bid Price Listing Requirement
Celsion Corp expected to post a loss of 90 cents a share - Earnings Preview
Brief: Celsion Reports DSMB Unanimous Recommendation To Continue Dosing Patients In Phase II Portion Of Study With Gen-1 In Advanced Ovarian Cancer
Brief: Celsion Corp Engages Bioqual For Non-Human Primate Challenge Study With Its SARS-COV-2 Vaccine
Brief: Celsion Corporation Announces Pricing Of $30 Million Registered Direct Offerings Of Convertible Redeemable Preferred Stock
Celsion Corp reports results for the quarter ended in September - Earnings Summary